[go: up one dir, main page]

MA26542A1 - Derives oxindole substitues. - Google Patents

Derives oxindole substitues.

Info

Publication number
MA26542A1
MA26542A1 MA25240A MA25240A MA26542A1 MA 26542 A1 MA26542 A1 MA 26542A1 MA 25240 A MA25240 A MA 25240A MA 25240 A MA25240 A MA 25240A MA 26542 A1 MA26542 A1 MA 26542A1
Authority
MA
Morocco
Prior art keywords
oxindole derivatives
substituted oxindole
substituted
derivatives
oxindole
Prior art date
Application number
MA25240A
Other languages
English (en)
Inventor
Stephen Vernon Frye
Lee Frederick Kuyper
James Marvin Veal
Stephen Thomas Davis
Scott Howard Dickerson
Philip Antony Harris
Robert Neil Hunter Iii
Karen Elisabeth Lackey
Michael Joseph Luzzio
Duncan Herrick Walker
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA26542A1 publication Critical patent/MA26542A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA25240A 1997-09-05 1998-09-02 Derives oxindole substitues. MA26542A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9718913.8A GB9718913D0 (en) 1997-09-05 1997-09-05 Substituted oxindole derivatives

Publications (1)

Publication Number Publication Date
MA26542A1 true MA26542A1 (fr) 2004-12-20

Family

ID=10818643

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25240A MA26542A1 (fr) 1997-09-05 1998-09-02 Derives oxindole substitues.

Country Status (23)

Country Link
US (4) US6387919B1 (fr)
EP (1) EP1009738B1 (fr)
JP (1) JP2001517652A (fr)
KR (1) KR20010023695A (fr)
CN (1) CN1278794A (fr)
AR (1) AR015432A1 (fr)
AT (1) ATE267170T1 (fr)
AU (1) AU747506B2 (fr)
BR (1) BR9812048A (fr)
CA (1) CA2302572A1 (fr)
CO (1) CO4960633A1 (fr)
DE (1) DE69824014T2 (fr)
EE (1) EE200000117A (fr)
ES (1) ES2221211T3 (fr)
GB (1) GB9718913D0 (fr)
HU (1) HUP0004490A3 (fr)
MA (1) MA26542A1 (fr)
PE (1) PE107699A1 (fr)
PL (1) PL338991A1 (fr)
TR (1) TR200001174T2 (fr)
TW (1) TW520358B (fr)
WO (1) WO1999015500A1 (fr)
ZA (1) ZA988078B (fr)

Families Citing this family (260)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407132B1 (en) * 1997-07-25 2002-06-18 James Black Foundation Limited Substituted imidazole derivatives and their use as histamine H3 receptor ligands
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19824922A1 (de) * 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US6319918B1 (en) 1998-06-04 2001-11-20 Boehringer Ingelheim Pharma Kg Substituted indolinones with kinase inhibitory activity
WO2000035920A2 (fr) * 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4,5-azolo-oxindoles
AU760039B2 (en) 1998-12-17 2003-05-08 F. Hoffmann-La Roche Ag 4-aryloxindoles as inhibitors of JNK protein kinases
JP2002532503A (ja) * 1998-12-17 2002-10-02 エフ．ホフマン−ラ ロシュ アーゲー プロテインキナーゼ阻害剤としての４，５−ピラジノオキシンドール
US6153634A (en) 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
ES2192877T3 (es) * 1998-12-17 2003-10-16 Hoffmann La Roche 4-alquenil (y alquinil) oxindoles como inhibidores de kinasas ciclina-dependientes, en particular cdk2.
DE60045474D1 (de) 1999-01-13 2011-02-17 Univ New York State Res Found Neues verfahren zum erschaffen von proteinkinase-inhibitoren
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
US6492398B1 (en) * 1999-03-04 2002-12-10 Smithkline Beechman Corporation Thiazoloindolinone compounds
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
GB9904930D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Thiazoloindolinone compounds
GB9904932D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
DE19924401A1 (de) * 1999-05-27 2000-11-30 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE50012136D1 (en) * 1999-08-27 2006-04-13 Boehringer Ingelheim Pharma Substituierte indolinone als tyrosinkinase inhibitoren
US6552008B1 (en) * 1999-09-24 2003-04-22 Smithkline Beecham Corporation Thrombopoietin mimetics
DE19949209A1 (de) * 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
UA75054C2 (uk) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
CA2369502A1 (fr) * 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Compositions utiles comme inhibiteurs de erk
US6620818B1 (en) * 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
CA2398446A1 (fr) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles permettant d'inhiber des proteines kinases
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
US6534531B2 (en) * 2000-04-27 2003-03-18 Bristol-Myers Squibb Company Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
EP1277478A4 (fr) * 2000-04-28 2007-09-26 Astellas Pharma Inc Compositions medicinales destinees a supprimer la production de beta-amyloide
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
GB0016454D0 (en) 2000-07-04 2000-08-23 Hoffmann La Roche Thienopyrrolidinones
AU2001277285A1 (en) 2000-08-09 2002-02-18 Agouron Pharmaceuticals, Inc. Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases
MXPA03001452A (es) 2000-08-18 2004-05-04 Agouron Pharma Hidroximino-fluorenos heterociclicos y su uso para la inhibicion de las proteinas cinasas.
EP1339680A1 (fr) * 2000-09-01 2003-09-03 Glaxo Group Limited Derives d'oxindole substitues utilises comme inhibiteurs de la tyrosine kinase
JP2004508372A (ja) 2000-09-01 2004-03-18 グラクソ　グループ　リミテッド オキシインドール誘導体
AU8664701A (en) * 2000-09-01 2002-03-22 Glaxo Group Ltd Oxindole derivatives
EP1201765A3 (fr) * 2000-10-16 2003-08-27 Axxima Pharmaceuticals Aktiengesellschaft Kinases cellulaires impliqués dans l'infection par cytomégalovirus et leur inhibition
DE10054019A1 (de) * 2000-11-01 2002-05-23 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US6638965B2 (en) 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
DE10117204A1 (de) * 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
SE0101230L (sv) * 2001-04-06 2002-10-07 Innoventus Project Ab Ny användning av en tyrosinkinasinhibitor
US20050090498A1 (en) * 2001-05-24 2005-04-28 Kiyohiro Samizu 3-Quinolin-2(1h)-ylideneindolin-2-one derivative
US7727731B2 (en) 2001-06-29 2010-06-01 Ab Science Potent, selective and non toxic c-kit inhibitors
ATE343415T1 (de) 2001-06-29 2006-11-15 Ab Science Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
JP2004537537A (ja) 2001-06-29 2004-12-16 アブ サイエンス 炎症性疾患を治療するためのチロシンキナーゼ阻害剤の使用法
DE60225590T2 (de) * 2001-09-20 2008-09-25 Ab Science C-kithemmer zur behandlung von bakteriellen infektionen
DE60227701D1 (de) * 2001-09-20 2008-08-28 Ab Science Die verwendung von c-kithemmern zur förderung des haarwuchses
WO2003027109A1 (fr) * 2001-09-27 2003-04-03 Allergan, Inc. 3-(heteroarylamino)methylene-1, 3-dihydro-2h-indol-2-ones, inhibiteurs de kinase
CA2461812C (fr) * 2001-09-27 2011-09-20 Allergan, Inc. L'utilisation de 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones en tant qu'inhibiteurs de kinases
WO2003033491A1 (fr) * 2001-10-16 2003-04-24 Nippon Kayaku Kabushiki Kaisha Composition medicinale de prevention ou de soulagement d'effets secondaires chez les patients souffrant de cancer et composition anticancereuse medicinale
CA2464214C (fr) * 2001-10-22 2011-02-08 The Research Foundation Of State University Of New York Inhibiteurs de proteines kinases et de proteines phosphatases, methodes d'identification et methodes d'utilisation associees
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2002354499A1 (en) * 2001-12-18 2003-06-30 Kyowa Hakko Kogyo Co., Ltd. Indole derivative
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
US7482366B2 (en) * 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
FR2836914B1 (fr) 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
CN1650001A (zh) * 2002-04-30 2005-08-03 爱尔康公司 作为降低眼内压和治疗青光眼性视网膜病变 /眼神经病的独特手段的调控、抑制或调节结缔组织生长因子( ctgf)的活性和／或表达的药物
AR040083A1 (es) 2002-05-22 2005-03-16 Smithkline Beecham Corp Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
AU2003259689A1 (en) * 2002-08-07 2004-02-25 Synaptic Pharmaceutical Corporation 3-imino-2-indolones for the treatment of depression and/or anxiety
US20040082615A1 (en) * 2002-08-07 2004-04-29 Michael Konkel 3-Imino-2-indolones for the treatement of depression and/or anxiety
GB0225873D0 (en) * 2002-11-06 2002-12-11 Cyclacel Ltd Combination
WO2004048366A1 (fr) * 2002-11-22 2004-06-10 Yamanouchi Pharmaceutical Co., Ltd. Derives 2-oxoindoline
ATE354096T1 (de) 2002-12-23 2007-03-15 Astex Therapeutics Ltd Synthese und screening von liganden mit hilfe von röntgenkristallographie
KR101201603B1 (ko) 2003-07-30 2012-11-14 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방에 사용하기 위한2,4-피리미딘디아민 화합물
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
GB0328180D0 (en) * 2003-12-04 2004-01-07 Cyclacel Ltd Combination
DE102004012069A1 (de) * 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue aryl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
WO2005118551A2 (fr) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Composes modulant l'activite de la thrombopoietine et methodes associees
JP4728340B2 (ja) * 2004-10-25 2011-07-20 リガンド・ファーマシューティカルズ・インコーポレイテッド トロンボポエチン活性を変調する化合物および変調方法
GT200500321A (es) * 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
US20080125432A1 (en) 2004-12-01 2008-05-29 Devgen Nv 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family
EP1969940A3 (fr) * 2004-12-17 2008-12-10 Devgen NV Compositions nematicides
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2006101937A1 (fr) * 2005-03-18 2006-09-28 Janssen Pharmaceutica N.V. Acylhydrazones en tant que modulateurs de kinase
WO2006119660A1 (fr) * 2005-05-11 2006-11-16 Givaudan Sa Procede d'encapsulation
EP1904457B1 (fr) 2005-06-08 2017-09-06 Rigel Pharmaceuticals, Inc. Compositions et procedes d'inhibition de la voie jak
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7692005B2 (en) 2005-07-13 2010-04-06 Allergan, Inc. Kinase inhibitors
US7749530B2 (en) 2005-07-13 2010-07-06 Allergan, Inc. Kinase inhibitors
EP1902024B1 (fr) * 2005-07-13 2013-04-17 Allergan, Inc. Inhibiteurs de kinases
GB0523041D0 (en) * 2005-11-11 2005-12-21 Cyclacel Ltd Combination
JP2009528295A (ja) 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
US8987474B2 (en) * 2006-04-07 2015-03-24 University Of South Florida Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8036664B2 (en) * 2006-09-22 2011-10-11 Kineto Wireless, Inc. Method and apparatus for determining rove-out
US20100087464A1 (en) * 2006-10-06 2010-04-08 Irm Llc Protein kinase inhibitors and methods for using thereof
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
ES2369617T3 (es) * 2007-02-13 2011-12-02 Ab Science Procedimiento para la síntesis de compuestos de 2-aminotiazol como inhibidores de la quinasa.
US20100143440A1 (en) * 2007-04-30 2010-06-10 The Uab Research Foundation Ul97 inhibitors for treatment of proliferative disorders
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
US7863315B2 (en) * 2008-01-15 2011-01-04 Shenzhen Chipscreen Biosciences, Ltd. 2-indolinone derivatives as selective histone deacetylase inhibitors
PL2265607T3 (pl) 2008-02-15 2017-07-31 Rigel Pharmaceuticals, Inc. Związki pirymidyno-2-aminowe i ich zastosowanie jako inhibitory kinaz JAK
US20110092452A1 (en) * 2008-03-05 2011-04-21 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating pancreatic cancer
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
BRPI0910921B1 (pt) 2008-04-16 2022-06-21 Portola Pharmaceuticals, Inc Inibidores de proteína syk quinase, composição farmacêutica, kit e usos dos referidos inibidores
EP2116236A1 (fr) 2008-04-21 2009-11-11 Université de Mons-Hainaut Dérivés de bisbenzamidine pour une utilisation en tant qu'antioxydants
CA2723185A1 (fr) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibiteurs de proteines kinases
WO2009135000A2 (fr) * 2008-04-30 2009-11-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibition de la protéine tyrosine phosphatase shp2/ptpn11 par nsc-117199 et analogues
CN102098918A (zh) * 2008-05-13 2011-06-15 帕纳德制药公司 用于治疗癌症和神经退行性疾病的生物活性化合物
WO2009150405A1 (fr) 2008-06-09 2009-12-17 Cyclacel Limited Combinaison de sapacitabine (cndac) et d’inhibiteurs d’adn méthyltransférase tels que la décitabine et la procaïne
WO2010039997A2 (fr) * 2008-10-01 2010-04-08 The University Of North Carolina At Chapel Hill Protection hématopoïétique contre les composés chimiothérapeutiques au moyen d'inhibiteurs sélectifs des kinases dépendant des cyclines 4/6
US20110224221A1 (en) * 2008-10-01 2011-09-15 Sharpless Norman E Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
WO2010121212A2 (fr) 2009-04-17 2010-10-21 H. Lee Moffit Cancer Center And Research Institute, Inc. Inhibiteurs d'échafaudage d'indoline shp-2 et procédé de traitement du cancer
EP2429566B1 (fr) * 2009-05-13 2016-01-06 The University of North Carolina At Chapel Hill Inhibiteurs de kinases cycline-dépendantes et leurs procédés d'utilisation
KR20120015355A (ko) 2009-05-29 2012-02-21 글락소스미스클라인 엘엘씨 트롬보포이에틴 효능제 화합물의 투여 방법
BR112012002001A2 (pt) * 2009-07-28 2016-05-10 Rigel Pharmaceuticals Inc método para tratar uma doença e/ou distúrbio do olho, formulação farmacêutica, e, kit
EP2483407A2 (fr) 2009-09-30 2012-08-08 President and Fellows of Harvard College Procédés de modulation de l'autophagie par la modulation de produits géniques renforçant l'autophagie
US8652534B2 (en) 2009-10-14 2014-02-18 Berry Pharmaceuticals, LLC Compositions and methods for treatment of mammalian skin
RU2553681C2 (ru) * 2009-10-29 2015-06-20 Вектура Лимитед N-содержащие гетероарильные производные в качестве ингибиторов jak3 киназы
US20120328568A1 (en) 2010-02-12 2012-12-27 Emory University Compositions and uses of lectins
WO2011107608A1 (fr) 2010-03-02 2011-09-09 Amakem Nv Amides hétérocycliques en tant qu'inhibiteurs de rock
CA2803697A1 (fr) 2010-06-25 2011-12-29 Facultes Universitaires Notre Dame De La Paix Derives de la beta-carboline utiles dans le traitement de troubles proliferatifs
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
CA2808655C (fr) 2010-08-18 2019-11-26 Emory University Composes et compositions pour ossification et procedes associes a ceux-ci
WO2012022780A1 (fr) 2010-08-19 2012-02-23 Université Libre de Bruxelles Dérivés d'acide 18β-glycyrrhétinique ayant une activité antitumorale
CN106967074A (zh) 2010-10-25 2017-07-21 G1治疗公司 Cdk抑制剂
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
WO2012058211A2 (fr) 2010-10-29 2012-05-03 Emory University Dérivés quinazoline, compositions et utilisations correspondantes
TW201300360A (zh) 2010-11-01 2013-01-01 Portola Pharm Inc 做為ｊａｋ激酶調節劑之菸鹼醯胺
GB201019043D0 (en) 2010-11-10 2010-12-22 Protea Biopharma N V Use of 2',5'-oligoadenylate derivative compounds
CN103501789A (zh) 2010-11-17 2014-01-08 北卡罗来纳大学查珀尔希尔分校 通过抑制增殖性激酶cdk4和cdk6保护肾组织免于局部缺血
CA2819468C (fr) 2010-12-03 2019-01-29 Emory University Modulateurs du recepteur cxcr4 de chimiokine et utilisations associees
US8691777B2 (en) 2011-01-27 2014-04-08 Emory University Combination therapy
CA2827392A1 (fr) 2011-02-24 2012-08-30 Emory University Compositions antagonistes de noggine pour ossification et procedes associes a celles-ci
US11179500B2 (en) 2011-02-24 2021-11-23 Emory University JAB1 inhibitory compositions for ossification and methods related thereto
EP2691095B1 (fr) 2011-03-31 2017-07-05 Emory University Composés d'imidazolylamide et leurs utilisations
PL2696878T3 (pl) 2011-04-14 2020-01-31 Cyclacel Limited Schemat dawkowania dla sapacytabiny i decytabiny w kombinacji do leczenia ostrej białaczki szpikowej
EP2699539B1 (fr) 2011-04-21 2019-03-06 Emory University Dérivés cyclopropylés et leurs procédés d'utilisation
GB201107223D0 (en) 2011-04-29 2011-06-15 Amakem Nv Novel rock inhibitors
AU2012252433A1 (en) 2011-05-09 2013-11-07 Universiteit Antwerpen Activity-based probes for the urokinase plasminogen activator
GB201108225D0 (en) 2011-05-17 2011-06-29 Amakem Nv Novel KBC inhibitors
CA2839956A1 (fr) 2011-06-20 2012-12-27 Emory University Antagonistes du recepteur ep2 des prostaglandines, derives, compositions et utilisations associes
GB201113689D0 (en) 2011-08-09 2011-09-21 Amakem Nv Novel PDE4 inhibitors
US9040567B2 (en) 2011-08-19 2015-05-26 Emory University BAX agonist, compositions, and methods related thereto
GB201114854D0 (en) 2011-08-29 2011-10-12 Amakem Nv Novel rock inhibitors
WO2013030365A1 (fr) 2011-08-31 2013-03-07 Amakem Nv Nouveaux inhibiteurs de kinase rock
WO2013046029A1 (fr) 2011-09-30 2013-04-04 Ipsen Pharma S.A.S. Inhibiteurs macrocycliques de la kinase lrrk2
WO2013045653A1 (fr) 2011-09-30 2013-04-04 Oncodesign S.A. Inhibiteurs de kinase flt3 macrocycliques
GB201119358D0 (en) 2011-11-10 2011-12-21 Lewi Paulus J Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
DE102011119127A1 (de) * 2011-11-22 2013-05-23 Merck Patent Gmbh 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
US9359308B2 (en) 2011-11-23 2016-06-07 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
EP2810198B1 (fr) 2012-01-30 2023-07-12 Universiteit Gent Composés anti-invasifs
GB201204756D0 (en) 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections
EP2831080B1 (fr) 2012-03-29 2017-03-15 Francis Xavier Tavares Lactames inhibiteurs de kinases
US20150110723A1 (en) 2012-05-31 2015-04-23 Emory University Quinazoline derivatives, compositions, and uses related thereto
US9593125B2 (en) 2012-07-27 2017-03-14 Emory University Heterocyclic flavone derivatives, compositions, and methods related thereto
EP2903970A4 (fr) 2012-10-08 2016-11-30 Portola Pharm Inc Inhibiteurs substitués de pyrimidinyl kinase
US9877981B2 (en) 2012-10-09 2018-01-30 President And Fellows Of Harvard College NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation
EP2914585B1 (fr) 2012-11-05 2018-03-07 Emory University 7,8-dihydroxyflavone et dérivés de flavone 7,8-substituée, compositions et méthodes associées
WO2014072419A1 (fr) 2012-11-08 2014-05-15 Universiteit Antwerpen Nouveaux composés anti-vih
DK2951172T3 (en) 2013-01-29 2017-07-17 Redx Pharma Plc PYRIDINE DERIVATIVES LIKE SOFT ROCK INHIBITORS
EP2968290B1 (fr) 2013-03-15 2019-09-25 G1 Therapeutics, Inc. Protection transitoire de cellules normales pendant une chimiothérapie
US20140271460A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly Active Anti-Neoplastic and Anti-Proliferative Agents
SG11201507493SA (en) 2013-03-15 2015-10-29 Oncodesign Sa Macrocyclic salt-inducible kinase inhibitors
US9572815B2 (en) 2013-03-15 2017-02-21 St. Jude Children's Research Hospital Methods and compositions of p27KIP1 transcriptional modulators
KR101548803B1 (ko) * 2013-09-09 2015-09-01 경북대학교병원 ３­（６­（４­（트리플루오로메톡시）페닐아미노）피리미딘­４­일）벤자미드 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물
ES2927955T3 (es) 2013-09-11 2022-11-14 Univ Emory Composiciones de nucleótidos y nucleósidos y sus usos
WO2015055796A1 (fr) 2013-10-16 2015-04-23 Université Libre de Bruxelles Formulations utiles dans le traitement de maladies prolifératives affectant le tractus respiratoire
CN103588758A (zh) * 2013-11-04 2014-02-19 南京大学 一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的合成、制备及其在抗癌药物中的应用
HUE038831T2 (hu) 2013-11-12 2018-11-28 Univ Brussel Vrije RNS transzkripciós vektor és felhasználásai
EP3074010A4 (fr) 2013-11-27 2017-10-25 Redwood Bioscience, Inc. Composés hydrazinyl-pyrrolo et procédés de production d'un conjugué
KR101602203B1 (ko) * 2014-03-11 2016-03-11 경북대학교병원 N­（2­하이드록시에틸）­3­（6­（4­（트리플루오로메톡시）페닐아미노）피리미딘-4-일）벤자미드 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물
WO2015150337A1 (fr) 2014-04-01 2015-10-08 Amakem Nv Inhibiteurs de la lim kinase
WO2015150472A2 (fr) 2014-04-01 2015-10-08 Université Libre de Bruxelles Nouvelles stratégies de traitement du mélanome
US20150297607A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use in the Protection of Normal Cells During Chemotherapy
US9980936B2 (en) 2014-05-05 2018-05-29 Emory University BH4 antagonists and methods related thereto
EP3143005B1 (fr) 2014-05-16 2021-07-07 Emory University Modulateurs des récepteurs ccr5 et cxcr4 de la chimiokine et et leurs utilisations
EP3180003B1 (fr) 2014-07-01 2022-01-12 The Regents of the University of California Inhibiteurs de pkc-epsilon
US10023602B2 (en) 2014-07-08 2018-07-17 Universiteit Gent Hamamelitannin analogues and uses thereof
WO2016040858A1 (fr) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinaisons et régimes posologiques pour traiter des tumeurs rb-positives
WO2016040848A1 (fr) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Traitement de tumeurs rb-négatives en utilisant des inhibiteurs de la topoisomérase en association avec des inhibiteurs des kinases cycline-dépendantes 4/6
JP2017529365A (ja) 2014-09-17 2017-10-05 オンコデザイン エス．ア． 大環状ｌｒｒｋ２キナーゼ阻害剤
EA032872B1 (ru) 2014-09-17 2019-07-31 Онкодизайн С.А. Макроциклические ингибиторы rip2-киназы
WO2016083490A1 (fr) 2014-11-27 2016-06-02 Remynd Nv Composés pour le traitement de maladies associées à la substance amyloïde
CA2969372C (fr) 2014-12-15 2023-05-16 Emory University Phosphoramidates pour le traitement du virus de l'hepatite b
HRP20211456T1 (hr) 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
WO2016146651A1 (fr) 2015-03-16 2016-09-22 Oncodesign Sa Inhibiteurs macrocycliques de récepteur kinase de type activine
JP7193232B2 (ja) 2015-04-28 2022-12-20 ニューサウス イノベーションズ ピーティーワイ リミテッド 化学療法及び放射線療法誘発性認知機能障害、神経障害及び不活動を治療するためのｎａｄ＋の標的化
EP3804706B1 (fr) 2015-05-29 2023-08-23 Emory University 2-amino-n'-benzylidène-acétohydrazides et dérivés pour la prise en charge de maladies médiées par la protéine cftr
EP3310783B1 (fr) 2015-06-18 2020-11-04 Ting Therapeutics LLC Compositions de prévention de la perte d'audition
US12102689B2 (en) 2015-11-09 2024-10-01 R.P. Scherer Technologies, Llc Anti-CD22 antibody-maytansine conjugates and methods of use thereof
EP3423113B1 (fr) 2016-02-29 2020-09-02 Oncodesign S.A. Inhibiteur d'egfr macrocyclique radiomarqué
WO2017157882A1 (fr) 2016-03-14 2017-09-21 Université Catholique de Louvain Inhibiteurs de la voie de biosynthèse de la sérine
US11077110B2 (en) 2016-03-18 2021-08-03 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
EP3448392A4 (fr) 2016-04-28 2020-01-15 Emory University Compositions thérapeutiques à base de nucléotides et nucléosides contenant un alcyne et utilisations associées
EP3458072B1 (fr) 2016-05-19 2020-09-30 Universiteit Antwerpen Bis(acétamidophényl) guanidinophénylethylphosphonates pour utilisation dans la prévention et/ou le traitement de maladies associées similaires
BE1023757B1 (nl) 2016-06-30 2017-07-12 Yun NV Bewaring van micro-organismen
WO2018065387A1 (fr) 2016-10-04 2018-04-12 Universiteit Gent Nouveaux analogues du hamamélitannin et leurs utilisations
CN109923123B (zh) 2016-10-14 2024-01-23 爱默蕾大学 具有结合或阻断pd-l1的分子的纳米颗粒及其在治疗癌症中的用途
WO2018081442A1 (fr) 2016-10-26 2018-05-03 Emory University Complexes de polyoxométallate et leurs utilisations dans la prise en charge du cancer
US10738002B2 (en) 2016-11-24 2020-08-11 Universitair Ziekenhuis Antwerpen Halogenated benzotropolones as ATG4B inhibitors
JP2020513418A (ja) 2016-12-13 2020-05-14 エモリー ユニバーシティ ウイルス感染を管理するためのポリペプチド
EP3565558B1 (fr) 2017-01-06 2023-12-06 G1 Therapeutics, Inc. Polythérapie avec un composé serd et un inhibiteur cdk4/6 pour le traitement du cancer
US20190388426A1 (en) 2017-01-30 2019-12-26 Université de Liège Perk and ire-1a inhibitors against neurodevelopmental disorders
IL269379B (en) 2017-02-21 2022-06-01 Univ Emory Chemokine cxcr4 receptor modulators and uses related thereto
US10981896B2 (en) 2017-03-02 2021-04-20 Board Of Regents, The University Of Texas System Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase
CN106977508A (zh) * 2017-05-05 2017-07-25 遵义医学院 具有靛红结构的吡唑衍生物用于防治肿瘤的药物及其制法
US12178805B2 (en) 2017-05-11 2024-12-31 Remynd N.V. Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders
EA201992397A1 (ru) 2017-05-11 2020-03-16 Реминд Н.В. Соединения для лечения эпилепсии, нейродегенеративных нарушений и других нарушений цнс
US11661581B2 (en) * 2017-05-25 2023-05-30 University Of Massachusetts Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells
RU2019142591A (ru) 2017-06-29 2021-07-29 Г1 Терапьютикс, Инк. Морфологические формы g1t38 и способы их получения
ES2995458T3 (en) 2017-12-07 2025-02-10 Univ Emory N4-hydroxycytidine derivative and anti-viral uses related thereto
US20210145838A1 (en) 2018-04-05 2021-05-20 Universiteit Hasselt Selective pde4d inhibitors against demyelinating diseases
WO2020002715A1 (fr) 2018-06-29 2020-01-02 Rejuvenate Biomed Association pharmaceutique destinée à être utilisée dans des maladies liées à l'âge et/ou dégénératives
EP3833343B1 (fr) 2018-08-07 2024-02-21 Emory University Dérivés hétérocycliques de flavone, compositions et procédés associés
EP3840756A4 (fr) 2018-08-24 2022-04-27 G1 Therapeutics, Inc. Synthèse améliorée de la 1,4-diazaspiro[5.5]undécan-3-one
US20210292766A1 (en) 2018-08-29 2021-09-23 University Of Massachusetts Inhibition of Protein Kinases to Treat Friedreich Ataxia
MX2021003945A (es) * 2018-10-05 2021-05-27 Ichnos Sciences S A Compuestos de indolinona para uso como inhibidores de map4k1.
EP3941916A4 (fr) 2019-03-20 2022-11-23 Emory University Antagonistes du récepteur ep2 de la prostaglandine, dérivés, et utilisations associés
WO2020229595A1 (fr) 2019-05-14 2020-11-19 Molecular Targeted Radiopharmaceuticals Holding Gmbh (Mtr) Dérivés de quinazoline-2,4-dione utilisés en tant qu'inhibiteurs de parp
EP4003996A1 (fr) 2019-07-22 2022-06-01 Radius Pharmaceuticals, Inc. Composés modulant les récepteurs des oestrogènes
US20230130598A1 (en) 2020-02-24 2023-04-27 Katholieke Universiteit Leuven Pyrrolopyridine and imidazopyridine antiviral compounds
GB202003240D0 (en) 2020-03-05 2020-04-22 Ecosynth Nv Antiviral treatment
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
US20240350492A1 (en) 2020-07-10 2024-10-24 Ting Therapeutics Llc Methods for the Prevention and Treatment of Hearing Loss
WO2022157381A1 (fr) 2021-01-25 2022-07-28 Universiteit Hasselt Phlorétine destinée à être utilisée dans le traitement de maladies neurodégénératives et démyélinisantes
US20240325363A1 (en) * 2021-03-12 2024-10-03 Oncocross Co.,Ltd. Composition for treatment of anticancer agent-resistant cancer
WO2023009438A1 (fr) 2021-07-26 2023-02-02 Celcuity Inc. 1-(4-{[4-(diméthylamino)pipéridin-1-yl]carbonyl}phényl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phényl]urée (gedatolisib) et ses combinaisons pour une utilisation dans le traitement du cancer
US20240368133A1 (en) 2021-07-30 2024-11-07 Confo Therapeutics N.V. Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling
EP4387629A1 (fr) 2021-08-18 2024-06-26 Katholieke Universiteit Leuven KU Leuven Research & Development Analogues de ribonucléoside 7-déazapurine 6-substitués et 6,7-disubstitués
EP4405357A1 (fr) 2021-09-23 2024-07-31 Katholieke Universiteit Leuven KU Leuven Research & Development Analogues de ribonucléosides dirigés contre le sars-cov-2
WO2023105283A1 (fr) 2021-12-08 2023-06-15 Fundacio Privada Institut De Recerca De La Sida - Caixa Inhibiteurs nucléosidiques de la transcriptase inverse destinés à être utilisés dans le traitement du syndrome de down et de la maladie d'alzheimer
WO2023111683A1 (fr) 2021-12-16 2023-06-22 Ascletis Bioscience Co., Ltd. Dérivés de n4-hydroxycytidine et leur utilisation comme agent antiviral
US11541071B1 (en) 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
WO2023139402A1 (fr) 2022-01-18 2023-07-27 Ascletis Bioscience Co., Ltd. Inhibiteurs de cystéine protéases et leurs procédés d'utilisation
US11760722B2 (en) 2022-01-18 2023-09-19 Ascletis Bioscience Co., Ltd. Inhibitors of cysteine proteases and methods of use thereof
WO2023180567A1 (fr) 2022-03-24 2023-09-28 Fundacion Privada Institut De Recerca De La Sida-Caixa Cyclodextrines destinées à être utilisées dans une thérapie contre une infection à coronavirus
WO2023241799A1 (fr) 2022-06-15 2023-12-21 Université Libre de Bruxelles Flavanols destinés à être utilisés dans le traitement d'infections rétrovirales
WO2024009120A1 (fr) 2022-07-08 2024-01-11 Ascletis Bioscience Co., Ltd. Dérivés de triazine et leurs procédés d'utilisation
CN115504968B (zh) 2022-11-21 2023-04-18 歌礼生物科技（杭州）有限公司 三嗪衍生物
WO2024193451A1 (fr) 2023-03-17 2024-09-26 Ascletis BioScience Co., Ltd Dérivés de triazine, leur procédé de fabrication et leur procédé d'utilisation

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2447940A1 (fr) 1979-02-05 1980-08-29 Ato Chimie Nouveaux (co)polycarbonates resistant au feu contenant des fonctions diesters ou hemiesters alcalins d'acides phosphoniques
WO1988007035A1 (fr) 1987-03-11 1988-09-22 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Derives d'hydroxystyrene
US5089516A (en) 1987-03-11 1992-02-18 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha 1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have tyrosine kinase inhibiting activity
US5202341A (en) 1987-03-11 1993-04-13 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene compounds having tyrosine kinase inhibiting activity
GB8816944D0 (en) * 1988-07-15 1988-08-17 Sobio Lab Compounds
JP2877508B2 (ja) 1989-02-08 1999-03-31 アボツト・ラボラトリーズ ５―リポキシゲナーゼ阻止剤としての４―ヒドロキシチアゾール
WO1991009598A1 (fr) 1990-01-05 1991-07-11 Pfizer Inc. Derives de l'azaoxindole
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
US5164404A (en) 1991-03-15 1992-11-17 Neurosearch A/S Hydrazone derivatives and their use
EP0584264A1 (fr) 1991-05-16 1994-03-02 Cold Spring Harbor Laboratory Cyclines du type d et leurs utilisations
GB9115160D0 (en) 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
CA2119443C (fr) 1991-09-20 1999-11-02 James M. Roberts Cycline e humaine
US5294538A (en) 1991-11-18 1994-03-15 Cold Spring Harbor Labs. Method of screening for antimitotic compounds using the CDC25 tyrosine phosphatase
US5770423A (en) 1991-11-18 1998-06-23 Cold Spring Harbor Laboratory Nucleic acids encoding cdc25 A and cdc25 B proteins and method of making cdc25 A and cdc25 B proteins
US5441880A (en) 1991-11-18 1995-08-15 Cold Spring Harbor Laboratory Human cdc25 genes, encoded products and uses thereof
WO1993024514A1 (fr) 1992-05-26 1993-12-09 Mitotix Cycline de type d et utilisations correspondantes
WO1994023029A1 (fr) 1993-03-31 1994-10-13 Monash University Sequence de nucleotides codant une proteine chromosomique, proteines chromosomiques associees et leurs utilisations
US5443962A (en) 1993-06-04 1995-08-22 Mitotix, Inc. Methods of identifying inhibitors of cdc25 phosphatase
GB9313638D0 (en) 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
US5496828A (en) * 1994-08-22 1996-03-05 Eli Lilly And Company Methods of inhibiting ulcerative mucositis
CA2235810C (fr) 1994-10-24 2010-02-09 Baylor College Of Medicine Inhibiteurs de synthese d'adn produits dans des cellules senescentes
GB9423997D0 (en) 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
GB9507298D0 (en) 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
ATE243034T1 (de) 1996-01-17 2003-07-15 Taiho Pharmaceutical Co Ltd Intimale verdickungsinhibitoren
US5672508A (en) 1996-01-23 1997-09-30 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
EP0788890A1 (fr) 1996-02-06 1997-08-13 Agfa-Gevaert N.V. Colorants et éléments donneur de colorant pour l'enregistrement par transfert thermique de colorant
CA2249603A1 (fr) 1996-03-29 1997-10-09 Pfizer Inc. Derives du benzyl(diene)-lactame, leur preparation et leur utilisation comme antagonistes/agonistes des recepteurs 5-ht1a- et/ou 5-ht1d
JP2001514484A (ja) 1996-08-21 2001-09-11 スージェン・インコーポレーテッド タンパク質チロシンキナーゼの結晶構造
DE69734521T9 (de) 1996-08-23 2006-12-07 Sugen, Inc., South San Francisco Kombinatorische indolinonbibliotheken und verwandte produkte und verfahren zur behandlung von erkrankungen
WO1998050356A1 (fr) * 1997-05-07 1998-11-12 Sugen, Inc. Derives de 2-indolinone utilises en tant que modulateurs de l'activite de la proteine kinase
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6319918B1 (en) 1998-06-04 2001-11-20 Boehringer Ingelheim Pharma Kg Substituted indolinones with kinase inhibitory activity
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
GB9904932D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
GB9904930D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Thiazoloindolinone compounds
US6620818B1 (en) * 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy

Also Published As

Publication number Publication date
AR015432A1 (es) 2001-05-02
EE200000117A (et) 2000-12-15
PE107699A1 (es) 1999-11-24
CN1278794A (zh) 2001-01-03
CA2302572A1 (fr) 1999-04-01
GB9718913D0 (en) 1997-11-12
EP1009738A1 (fr) 2000-06-21
AU747506B2 (en) 2002-05-16
KR20010023695A (ko) 2001-03-26
ATE267170T1 (de) 2004-06-15
US20030004351A1 (en) 2003-01-02
DE69824014T2 (de) 2005-05-12
ZA988078B (en) 2000-03-22
WO1999015500A1 (fr) 1999-04-01
US6541503B2 (en) 2003-04-01
US6387919B1 (en) 2002-05-14
DE69824014D1 (en) 2004-06-24
HUP0004490A3 (en) 2002-10-28
PL338991A1 (en) 2000-12-04
TW520358B (en) 2003-02-11
EP1009738B1 (fr) 2004-05-19
US6369086B1 (en) 2002-04-09
HUP0004490A2 (en) 2001-03-28
ES2221211T3 (es) 2004-12-16
BR9812048A (pt) 2000-09-26
CO4960633A1 (es) 2000-09-25
US20030069430A1 (en) 2003-04-10
TR200001174T2 (tr) 2000-08-21
JP2001517652A (ja) 2001-10-09
AU9740798A (en) 1999-04-12
US7105529B2 (en) 2006-09-12

Similar Documents

Publication Publication Date Title
MA26542A1 (fr) Derives oxindole substitues.
MA26504A1 (fr) Derives benzimidazole.
PT901474E (pt) Derivados de aril-pirimidina.
DE69736711D1 (de) Substituierte 6,5-heterobicyclische-derivate
DK0925298T3 (da) Substituerede 6,6-heterobicykliske derivater
DE69933287D1 (de) 12,13-modifizierte epothilon-derivate
NO990544L (no) Substituerte pyrido- eller pyrimido-inneholdende 6,6 eller 6,7-bycykliske derivater
NL300214I1 (nl) Chinazolinederivaten.
DK1000048T3 (da) Substituerede 1,2,3,4-tetrahydronapthalenderivater
TR199600883A2 (tr) Pürin-6-on türevleri.
DE69718771D1 (de) Substituierte 1,2,3,4-tetrahydronaphthalinderivate
ATE255098T1 (de) Substituierte chromanderivate
DK0922050T3 (da) 3-Descladinose-2,3-anhydroerythromycin-derivater
ATE255099T1 (de) Substituierte chromanderivate
EE200000447A (et) 1,3,4-oksadiasolooni derivaadid
TR199600715A2 (tr) Kefalosforin türevleri.
DZ2917A1 (fr) Nouveau 3-tetrahydropyridin-4-yl indoles.
TR199600064A2 (tr) 4-amino-benzoilguanidin-türevleri.
NL1013652A1 (nl) Piperazinonderivaten.
DK1068198T3 (da) 5-Heteroarylsubstituerede indoler
TR28915A (tr) Naftokinon türevleri.
TR199700219A3 (tr) 1,25-Dihidroksi-16, 22, 23-Trisdihidro-kolkalsiferol türevleri.
NO993024D0 (no) Polysakkarid-peptid-derivater
TR199700927A3 (tr) N-Benzilazolyum türevleri.
TR199802513A3 (tr) N-(4- Karbamimido- fenil)- fenilglisinamid türevleri.